Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H20N2O3.2ClH |
Molecular Weight | 313.221 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.CC(C)(C)NCC(O)C1=NC(CO)=C(O)C=C1
InChI
InChIKey=XIDFCZTVVCWBGN-UHFFFAOYSA-N
InChI=1S/C12H20N2O3.2ClH/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8;;/h4-5,11,13,15-17H,6-7H2,1-3H3;2*1H
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C12H20N2O3 |
Molecular Weight | 240.2988 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Pirbuterol (trade name Maxair) is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma. The pharmacologic effects of beta-adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-adenosine monophosphate (c-AMP). Increased c-AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells. Pirbuterol is used in asthma for reversal of acute bronchospasm, and also as a maintenance medication to prevent future attacks. It should be used in patients 12 years of age and older with or without concurrent theophylline and/or inhaled corticosteroid. After inhalation of doses up to 800 μg (twice the maximum recommended dose) systemic blood levels of pirbuterol are below the limit of assay sensitivity (2–5 ng/ml). A mean of 51% of the dose is recovered in urine as pirbuterol plus its sulfate conjugate following administration by aerosol. Pirbuterol is not metabolized by catechol-O-methyltransferase.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.2 μg/L |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIRBUTEROL plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
9.8 μg/L |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIRBUTEROL plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
PIRBUTEROL plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 ug single, respiratory Dose: 400 ug Route: respiratory Route: single Dose: 400 ug Sources: |
unhealthy, 32 years (range: 21-56 years) n = 14 Health Status: unhealthy Condition: asthma Age Group: 32 years (range: 21-56 years) Sex: M+F Population Size: 14 Sources: |
|
40 mg 1 times / day multiple, oral Highest studied dose Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy, 62 years (range 42-71 years) n = 26 Health Status: unhealthy Condition: chronic heart failure Age Group: 62 years (range 42-71 years) Sex: M+F Population Size: 26 Sources: |
Sample Use Guides
Bronchospasm, prevention and treatment: Inhalation: 1 to 2 inhalations (200mcg) every 4 to 6 hours; not to exceed 12 inhalations daily. Patients should be advised to promptly consult healthcare provider or seek medical attention if no relief from acute treatment
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17260025
MDA-MB-231, SF-539, ACHN, A-549, HCT-116, SNB-19 were used for activity evaluation. Cells (1x10^5) were plated in 60mm dishes and treated with various doses of ARA-211 (Pirbuterol) or vehicle for 48 h. Apoptosis was analysed using the Cell Death Detection ELISA (Roche, Indianapolis, IN, USA) measuring cytoplasmic histoneassociated mono- and oligonucleosome DNA fragments.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:35:05 GMT 2023
by
admin
on
Fri Dec 15 15:35:05 GMT 2023
|
Record UNII |
J6793T658K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
253-751-3
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
100000085311
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
68658
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
DBSALT000798
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
DTXSID5045120
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
J6793T658K
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
355078
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
235447
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
m8872
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
C76545
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
38029-10-6
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
SUB03868MIG
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY | |||
|
100415-23-4
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
SUPERSEDED | |||
|
CHEMBL1094966
Created by
admin on Fri Dec 15 15:35:06 GMT 2023 , Edited by admin on Fri Dec 15 15:35:06 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |